Objective. To evaluate the clinical potential of contrast-enhanced MRI with Gd-DTPA (gadopentetate dimeglumine) in the diagnosis of borderline ovarian tumors.
Methods. Thirteen patients with 14 borderline ovarian tumors were evaluated with serum levels of four tumor markers (CA125, CA19-9, SLX and CEA) and contrast-enhanced MRI.
Results. Among the 13 patients, five had normal serum levels of all four tumor markers, and five had high serum levels of plural tumor markers. The positive rates of CA125, CA19-9, SLX, and CEA were 46.2% (6/13), 38.5% (5/13), 30.8% (4/13), and 7.7% (1/13), respectively. With contrast-enhanced MRI, all 13 patients were diagnosed as having malignant tumors using the widely accepted criteria of MRI findings for the diagnosis of malignant ovarian tumors.
Conclusions. In the present study, all 14 borderline tumors had similar MRI findings to those of malignant tumors and were diagnosed as ovarian cancers with contrast-enhanced MRI, unrelated to the serum levels of tumor markers.